SECURITY AGREEMENTSecurity Agreement • February 11th, 2015 • Urigen Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This SECURITY AGREEMENT, dated as of June 23, 2014 (this “Agreement”), is among Urigen Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Urigen N.A., Inc., a Delaware corporation (the “Guarantor” and together with the Company, the “Debtors”), and Platinum-Montaur Life Sciences, LLC, a Delaware limited liability company (together with its successors and assigns, the “Secured Party”), as secured party for itself and the other Lenders (as defined below).
LICENSE AGREEMENTLicense Agreement • February 11th, 2015 • Urigen Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS LICENSE AGREEMENT (this “Agreement”) dated as of October 24, 2014 (the “Effective Date”), is entered into between URIGEN PHARMACEUTICALS, INC., a Delaware corporation (“Urigen”), with a place of business at 501 Silverside Road PMB# 95, Wilmington, Delaware 19809 and IMPRIMIS PHARMACEUTICALS, INC., a Delaware corporation (“Imprimis”), with a place of business at 12264 El Camino Real, Suite 350, San Diego, California 92130. The parties hereby agree as follows:
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 11th, 2015 • Urigen Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENT (the “Agreement”), dated as of June 23, 2014, between Urigen Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Platinum-Montaur Life Sciences, LLC (“Platinum”), and the other holders signatory hereto (the “Other Holders”).
GUARANTYGuaranty • February 11th, 2015 • Urigen Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
GUARANTY (this “Guaranty”), dated as of June 23, 2014, is by Urigen N.A., Inc., a Delaware corporation with an address of 501 Silverside Road, PMB #95, Wilmington, DE 19809 (the “Guarantor”), in favor of the parties set forth on Annex A hereto (together with their respective successors and assigns, the “Guaranteed Parties”).
FORMULATION AND USE AGREEMENTFormulation and Use Agreement • February 11th, 2015 • Urigen Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Formulation and Use Agreement (the “Agreement”) is made and entered into as of [ ] (the “Effective Date”), by and between Urigen Pharmaceuticals, Inc., a Delaware corporation, having its principal office at 1700 North Broadway, Suite 330, Walnut Creek, CA 94596 (“URIGEN”), and [ ], a compounding pharmacy having its principal office at [ ] (“PHARMACY”). URIGEN and PHARMACY are sometimes each hereinafter referred to as a "Party" or collectively as "Parties" to this Agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • February 11th, 2015 • Urigen Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
EMPLOYMENT AGREEMENT (this “Agreement”), dated as of February 6, 2015, between Urigen Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Ebrahim Versi, M.D., Ph. D. (“Executive,” together with the Company, the “Parties” and, each, a “Party”).
EMPLOYMENT AGREEMENTEmployment Agreement • February 11th, 2015 • Urigen Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
This Employment Agreement (this “Agreement”) is effective as of August 15, 2014 (the “Effective Date”), by and between Urigen Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Mark J. Rosenblum (the “Executive”).
EXCHANGE AND WAIVER AGREEMENT Dated as of April 25, 2014 by and among URIGEN PHARMACEUTICALS, INC., PLATINUM-MONTAUR LIFE SCIENCES, LLC AND THE OTHER LENDERS NAMED HEREINExchange and Waiver Agreement • February 11th, 2015 • Urigen Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
